<div id="readability-page-1"><div><p>Sunflower Pharmaceutical Group Co.,Ltd reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 1,683.98 million compared to CNY 2,966.91 million a year ago. Net loss was CNY 33.54 million compared to net income of CNY 586.84 million a year ago.</p><p>Basic loss per share from continuing operations was CNY 0.06 compared to basic earnings per share from continuing operations of CNY 1 a year ago. Diluted loss per share from continuing operations was CNY 0.06 compared to diluted earnings per share from continuing operations of CNY 1 a year ago.</p></div></div>

向日葵

<p>向日葵製藥集團有限公司報告了截至 2025 年 9 月 30 日的九個月內收益顯著下降。銷售額從去年同期的 29.6691 億元降至 16.8398 億元。公司面臨 3354 萬元的淨虧損，而去年同期則實現了 5868.4 萬元的淨收入。持續經營業務的基本和攤薄每股虧損均為 0.06 元，較去年每股盈利 1 元下降</p>

向日葵製藥集團有限公司公佈了截至2025年9月30日的九個月財務業績